-
The New England Journal of Medicine | RC48-C016 Study: A Major Breakthrough in China’s Urologic Oncology Field
The New England Journal of Medicine 2025-11-27View -
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial
Nature Medicine 2024-10-10View -
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia:First-in-Human,Phase I Trial
Journal of Clinical Oncology 2021-7-29View -
Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia
Journal of Hematology & Oncology 2023-4-5View -
Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia
Journal of Hematology & Oncology 2021-9-16View
- 1
- 2
- 3
- 4
- 5
- 6
- 7
